Initiator Pharma A/S (INIT.ST)
SEK 6.36
(1.92%)
SEK 6.36
(1.92%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -23.41 Thousand DKK | 39.07% |
| 2022 | -38.42 Thousand DKK | -77.68% |
| 2021 | -21.62 Thousand DKK | -132.56% |
| 2020 | -9299.00 DKK | -11.15% |
| 2019 | -8366.00 DKK | 26.86% |
| 2018 | -11.43 Thousand DKK | -39.83% |
| 2017 | -8180.00 DKK | -679.05% |
| 2016 | -1050.00 DKK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -2.9 Million DKK | -107663.74% |
| 2024 Q2 | -3.65 Million DKK | -26.06% |
| 2023 Q3 | -4.5 Million DKK | -54940.94% |
| 2023 Q4 | -2692.00 DKK | 99.94% |
| 2023 FY | -23.41 Thousand DKK | 39.07% |
| 2023 Q1 | -8.03 Million DKK | -145715.94% |
| 2023 Q2 | -8183.00 DKK | 99.9% |
| 2022 Q4 | -5509.00 DKK | 99.9% |
| 2022 FY | -38.42 Thousand DKK | -77.68% |
| 2022 Q3 | -5.52 Million DKK | -42967.69% |
| 2022 Q2 | -12.82 Thousand DKK | 99.91% |
| 2022 Q1 | -14.56 Million DKK | -114.98% |
| 2021 Q4 | -6.77 Million DKK | 23.48% |
| 2021 Q3 | -8.85 Million DKK | -100.86% |
| 2021 Q2 | -4.4 Million DKK | -178.35% |
| 2021 FY | -21.62 Thousand DKK | -132.56% |
| 2021 Q1 | -1.58 Million DKK | 18.89% |
| 2020 Q1 | -2.21 Million DKK | 8.21% |
| 2020 Q2 | -2.57 Million DKK | -16.39% |
| 2020 Q3 | -2.55 Million DKK | 0.97% |
| 2020 FY | -9299.00 DKK | -11.15% |
| 2020 Q4 | -1.95 Million DKK | 23.5% |
| 2019 Q4 | -2.41 Million DKK | -37.49% |
| 2019 FY | -8366.00 DKK | 26.86% |
| 2019 Q3 | -1.75 Million DKK | 40.37% |
| 2019 Q2 | -2.94 Million DKK | -134.5% |
| 2019 Q1 | -1.25 Million DKK | 43.14% |
| 2018 Q3 | -3.42 Million DKK | -16.09% |
| 2018 FY | -11.43 Thousand DKK | -39.83% |
| 2018 Q4 | -2.2 Million DKK | 35.62% |
| 2018 Q1 | -2.85 Million DKK | 18.15% |
| 2018 Q2 | -2.95 Million DKK | -3.61% |
| 2017 FY | -8180.00 DKK | -679.05% |
| 2017 Q1 | -882 Thousand DKK | 0.34% |
| 2017 Q3 | -2.13 Million DKK | -26.6% |
| 2017 Q4 | -3.48 Million DKK | -63.32% |
| 2017 Q2 | -1.68 Million DKK | -90.93% |
| 2016 Q4 | -885 Thousand DKK | -439.63% |
| 2016 Q2 | -2000.00 DKK | 0.0% |
| 2016 Q3 | -164 Thousand DKK | -8100.0% |
| 2016 FY | -1050.00 DKK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Lipum AB (publ) | 53 Thousand SEK | 144.174% |
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 99.985% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.007% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 100.056% |
| Mendus AB (publ) | 28.48 Million SEK | 100.082% |
| Genovis AB (publ.) | 54 Million SEK | 100.043% |
| CombiGene AB (publ) | -21.29 Million SEK | 99.89% |
| Intervacc AB (publ) | -13.79 Million SEK | 99.83% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 101.078% |
| Active Biotech AB (publ) | -1.67 Million SEK | 98.602% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 100.235% |
| Ziccum AB (publ) | -23.28 Million SEK | 99.899% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.001% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 99.981% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 100.087% |
| Aptahem AB (publ) | 2.63 Million SEK | 100.89% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 99.316% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 99.745% |
| Kancera AB (publ) | -1.96 Million SEK | 98.809% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 130.405% |
| Fluicell AB (publ) | 1.73 Million SEK | 101.347% |
| Saniona AB (publ) | 11.78 Million SEK | 100.199% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 99.542% |
| Biovica International AB (publ) | 6.87 Million SEK | 100.34% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 99.899% |
| AcouSort AB (publ) | 8.38 Million SEK | 100.279% |
| Xintela AB (publ) | 78 Thousand SEK | 130.015% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 100.209% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 100.066% |
| Abliva AB (publ) | -35.66 Million SEK | 99.934% |
| Corline Biomedical AB | 28.38 Million SEK | 100.082% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 100.834% |
| OncoZenge AB (publ) | 3000.00 SEK | 880.4% |
| Amniotics AB (publ) | -1.93 Million SEK | 98.787% |
| 2cureX AB (publ) | -37.48 Million SEK | 99.938% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 99.984% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 94.465% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.002% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 99.932% |
| I-Tech AB | 27.56 Million SEK | 100.085% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 100.033% |
| Cyxone AB (publ) | 2.61 Million SEK | 100.897% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 100.688% |
| Biosergen AB | -456 Thousand SEK | 94.866% |
| Cantargia AB (publ) | -3.45 Million SEK | 99.322% |
| NextCell Pharma AB | -43.74 Million SEK | 99.946% |
| Nanologica AB (publ) | -76 Thousand SEK | 69.195% |
| SynAct Pharma AB | -778 Thousand SEK | 96.991% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 87.869% |
| LIDDS AB (publ) | -12.92 Million SEK | 99.819% |
| BioInvent International AB (publ) | 71.46 Million SEK | 100.033% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 100.747% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| Alzinova AB (publ) | 19.87 Million SEK | 100.118% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 97.768% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 100.064% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 101.6% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -56.08% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 101.412% |
| Simris Alg AB (publ) | 2 Million SEK | 101.167% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 99.346% |